CXCR5 and neoplasm: As shown in Figure 5, tumor formation in the anti-CXCR5 treatment group was substantially delayed, with the median time to death in this group being 120.5 days (95% CI = 90-161 days), compared to 73 days (95% CI = 62-77 days) for the control group (p < 0.0007, log-rank test); this represents a 65% increase in the time to death in the treatment group.